Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Y6UU
|
||||
Former ID |
DCL000296
|
||||
Drug Name |
Atrasentan
|
||||
Synonyms |
Xinlay; Atrasentan [INN]; A 127722; A 147627; ABT 627; A-127722; A-147627; ABT-627; Xinlay (TN); A-127722.5; (+)-A 127722; (+)-A-127722; (11C)ABT-627; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid; 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid; 2R-(4-methoxyphenyl)-4S(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl)aminocarbonyl-methyl)-pyrrolidine-3R-carboxylic acid
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Hormone refractory prostate cancer [ICD9: 140-229, 185; ICD10:C61] | Withdrawn from market | [1], [2] | ||
Company |
Abbott
|
||||
Structure |
Download2D MOL |
||||
Formula |
C29H38N2O6
|
||||
InChI |
InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1
|
||||
InChIKey |
MOTJMGVDPWRKOC-QPVYNBJUSA-N
|
||||
CAS Number |
CAS 195733-43-8
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
535748, 10253652, 12014999, 14811316, 14909273, 46234806, 50068170, 50253083, 53788137, 53789849, 57348721, 103168476, 103948098, 113442732, 127346318, 128626310, 134338952, 134339653, 135115498, 135325628, 137006712, 141972835, 163620866, 163686195, 178100477, 179150068, 185974011, 198977266, 224005477, 226421083
|
||||
Target and Pathway | |||||
Target(s) | Endothelin-1 receptor | Target Info | Antagonist | [3] | |
KEGG Pathway | Calcium signaling pathway | ||||
cGMP-PKG signaling pathway | |||||
cAMP signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Vascular smooth muscle contraction | |||||
Renin secretion | |||||
Pathways in cancer | |||||
NetPath Pathway | IL4 Signaling Pathway | ||||
PANTHER Pathway | Endothelin signaling pathway | ||||
Pathway Interaction Database | Endothelins | ||||
EGFR-dependent Endothelin signaling events | |||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (q) signalling events | |||||
WikiPathways | Prostaglandin Synthesis and Regulation | ||||
GPCRs, Class A Rhodopsin-like | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
Peptide GPCRs | |||||
Endothelin Pathways | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
GPCRs, Other | |||||
References | |||||
REF 1 | Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3487). | ||||
REF 3 | Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.